Hold the core, honor the floor defense, and let one of two confirmed setups dictate re-engagement
Hold the core position at current exposure without adding at $266.69 resistance. Maintain stops at $254 (below 50 SMA/lower Bollinger confluence). Wait for either a pullback entry to $254-258 on >5M volume with reversal candle, or a breakout entry above $272 on >6M volume with MACD histogram turning positive. Reassess immediately following Q3 2026 earnings as the binary catalyst gate. The fundamental thesis (PEG 0.54, $16.87B FCF, defensive profile) remains intact and does not expire—the timing question is simply not answerable from current resistance levels with a binary catalyst ahead.
ABBV is a high-quality, defensive mega-cap pharma in the middle of a successful post-Humira transition, trading at a forward multiple (16.4x) and PEG ratio (0.54) that simply do not reflect the revenue acceleration and cash generation already showing up in the print.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | 229.96 | bullish |
| close_50_sma | 258.17 | bullish |
| close_10_ema | 263.91 | bullish |
| rsi | 59.76 | neutral |
| macd | 1.94 | neutral |
| macds | 2.05 | neutral |
| macdh | -0.10 | bearish |
| boll | 262.45 | neutral |
| boll_ub | 270.44 | neutral |
| boll_lb | 254.45 | neutral |
| atr | 5.49 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
ABBV is trading at a forward P/E of 16.4x with a PEG ratio of 0.54 — a screaming buy signal vs its own 5-year average of 18–20x and sector average of 17–19x
EV: $275–$290 · concedes: MACD histogram turned slightly negative (-0.10), though characterized as micro-stall within uptrend rather than reversal; Volume is below average at 4.41M, though characterized as confirming orderly accumulation rather than weakness; Sentiment reading is neutral (5.0/10) with low confidence — zero headlines, zero Reddit posts; Q3 earnings blackout period typical of late October explains quiet sentiment; Bear concerns on net debt, negative book value, and current ratio are structurally real but manageable given cash flow strength
ABBV at 266.69 is a negative expected value proposition with roughly 1:1 risk/reward and negative skew — the growth story is already priced in, the valuation is fair not cheap on normalized earnings, technicals show distribution at resistance, and the macro backdrop is a headwind that compresses multiples regardless of the dividend yield.
EV: -5.2% · concedes: Skyrizi and Rinvoq are real growth drivers with validated efficacy; The bull pitch was polished and well-constructed; Q1 2026 EPS beat was a real outcome, not fabricated; The MACD histogram at -0.10 is a small number in absolute terms — the bear's framing of it as significant was contested
→ vs conservative: Patent cliff and pipeline concerns are overblown; post-Humira transition is accelerating, not struggling
→ vs conservative: Waiting for pullback to 254-258 is letting perfect be the enemy of profitable; 50 SMA at 258 may be a magnet the market never gives
→ vs neutral: HOLD recommendation anchors to outdated stop below 200 SMA creating poor risk-reward; tightening stop to 50 SMA changes the math entirely
→ vs neutral: Confirmation on a breakout means giving up 2-4% of the move; buying momentum at higher prices with worse risk-reward
| vwma | ~264.00 | bullish |
Support: 254.45 · 258.17 · 264 | Resistance: 266.97 · 270.44
ABBV is in a constructive bullish regime with price 266.69 trading above all key moving averages (10 EMA 263.91, 50 SMA 258.17, 200 SMA 229.96). RSI at 59.76 offers neutral-bullish reading with room to extend, though the MACD histogram has turned slightly negative (-0.10) indicating a minor momentum stall near the upper Bollinger band. Support sits at 254.45 (lower Bollinger) and 258.17 (50 SMA), while resistance is at 270.44 (upper Bollinger) and 266.97 (prior swing high). ATR of 5.49 suggests typical daily range of ~$5.50. Volume at 4.41M is below the 5-7M average seen during August breakout, suggesting the current push lacks breakout conviction. Final recommendation is HOLD, with best entries on pullback to the 50 SMA/VWMA zone (~$258-264).
Market Cap
$471.27B
Trailing P/E
75.34x
Forward P/E
16.40x
PEG Ratio
0.54
Price/Book
-79.40x
EPS (TTM)
$3.54
Forward EPS
$16.26
Dividend Yield
2.60%
Beta
0.23
52-Week High
$269.39
52-Week Low
$190.75
50-Day MA
$257.97
200-Day MA
$231.73
TTM Revenue
$64.4B
Q1 2026 Revenue
$16.99B
Q1 2026 Revenue YoY Growth
+10.2%
Operating Margin
40.0%
EBITDA Margin (TTM)
47.8%
Net Margin (TTM)
9.8%
TTM Net Income
$6.27B
TTM Free Cash Flow
$16.87B
R&D % Revenue
~14%
SG&A % Revenue
~21.4%
Net Debt
$64.25B
Long-Term Debt
$62.48B
Short-Term Debt
$8.34B
Total Assets
$135.1B
Goodwill + Intangibles
$84.66B
Stockholders' Equity
-$5.94B
Current Ratio
0.81
Cash & Equivalents
$6.57B
Receivables
$13.82B
Inventory
$5.13B
Annual Dividend
~$12B
Strengths
Concerns
HOLD — AbbVie is a high-quality, defensive mega-cap pharma navigating a successful post-Humira transition. Revenue is accelerating to record levels ($16.99B in Q1 2026, +10.2% YoY), FCF is robust at $16.87B TTM, and valuation appears attractive on forward P/E (16.4x) and PEG (0.54x) bases versus sector peers. The principal risks — eventual biosimilar erosion on Skyrizi/Rinvoq, elevated leverage of $64.3B net debt, and negative book value — are being actively managed but warrant continued monitoring.
Macro: Sharp macro bifurcation: long-end Treasury yields at 23-year highs (10Y posted biggest monthly gain since 2022) with 96% odds of zero Fed cuts in 2026 and a hawkish Fed chorus, juxtaposed against equity indices at record highs. Iran war-driven oil inflation pulse keeping core CPI sticky but moderating (4.5%+ inflation in 2026 at 13%, down 3.5pp/wk). Recession odds fading (6%, down 2pp/wk). Moody's Zandi warns higher rates already damaging economy; Goldman sees rising rates threatening US debt sustainability. The dominant market interpretation: yields have made a regime step higher, but the runaway 6%+ scenario is fading (7% odds). Classic late-cycle, high-real-rates environment historically supportive of defensive, cash-flow-rich, dividend-paying names.